Leyden Laboratories BV

Leyden Labs is a clinical-stage biotechnology company that is fundamentally changing how we protect people from airborne viruses by building a new class of Mucosal Protection Products designed to protect at the site of respiratory infection—the airway mucosa. Its nasal sprays are designed to provide unmatched breadth of protection in the airway and overcome major limitations of vaccine-based protection. The company was founded in 2020 by the team that built Crucell into a global vaccine pioneer, including Dinko Valerio, Jaap Goudsmit, Ronald Brus, and Koenraad Wiedhaup. Two complementary lead programs have advanced into clinical development.

Leyden Labs was founded in 2020 by the team that built Crucell into a global vaccine pioneer. Following Crucell's acquisition by Johnson & Johnson in 2011, its technology and expertise became a cornerstone of Janssen Vaccines. Leyden Labs was established by renowned biotech leaders Dinko Valerio, Jaap Goudsmit, Ronald Brus, and Koenraad Wiedhaup. Born out of the pandemic of 2020, the company was founded on the belief that people deserved more adaptive, effective solutions than vaccines and social distancing. The founders reflected on a paradox: if airborne respiratory viruses enter through the nose, why are we protecting through the blood? They established the company around a different approach: administer broadly protective medicines directly to the respiratory mucosa where viruses invade. Since 2020, the company has continued to grow and be joined by leaders and founders including Linfa Wang, Anna Marie Pyle, Akiko Iwasaki, Kazuhiro Ito, Garth Rapeport, and Jag Shur.

Clinical-stage biotechnology company fundamentally changing how we protect people from airborne viruses.

• Mucosal Protection Products

  A new class of products designed to protect at the site of respiratory infection—the airway mucosa.

• Nasal sprays

  Designed to provide unmatched breadth of protection in the airway and overcome major limitations of vaccine-based protection.

• RIG-101

  A lead program that has advanced into clinical development; positive Phase 1 results reported, supporting advancement into Phase 2 to protect asthma patients.

1. 1Leyden Labs | Protecting Now From What Comes Nextleydenlabs.com
2. 2About us | Leyden Labsleydenlabs.com